Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BATON-CRC: Tivozanib + mFOLFOX6 in metastatic colorectal cancer
NCT01478594Phase 2Completed
- Sponsor
- AVEO Oncology
- Start
- Dec 2011
- Primary completion
- Sep 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of tivozanib in colorectal cancer (metastatic) (mCRC) (2 arms), sponsored by AVEO Oncology. Primary endpoint: Progression-Free Survival. Started Dec 2011; status: completed.
02
Drugs
tivozanib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01478594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478594.